(EA5142) Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Description: 

To evaluate whether adjuvant therapy with nivolumab will result in improved overall survival (OS) and/or disease-free survival (DFS) over standard observation in patients with Stage IB=4cm, II and IIIA, NSCLC following surgical resection and standard adjuvant therapy.

Study Number: 

NCG 290116

Phase: 
3
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02595944

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.